YQ23

News alerts, weekly reports and conference planners

Company:

New Beta Innovation

Drug class:

Oxygen carrier

Related drugs:

‹

›

2years

A Safety Study of YQ23 in Advanced Solid Tumors Patients (clinicaltrials.gov)

P1, N=3, Terminated, New Beta Innovation Limited | N=30 --> 3 | Trial completion date: Dec 2024 --> Jul 2023 | Active, not recruiting --> Terminated; Due to business decision

2 years ago

Enrollment change • Trial completion date • Trial termination

Keytruda (pembrolizumab) • YQ23

2years

YAN: YQ23 Study in Patients With Critical Limb Ischaemia (clinicaltrials.gov)

P1/2, N=5, Terminated, New Beta Innovation Limited | Phase classification: P1b/2a --> P1/2 | N=51 --> 5 | Trial completion date: Jun 2024 --> Aug 2023 | Active, not recruiting --> Terminated; Due to business decision

2 years ago

Phase classification • Enrollment change • Trial completion date • Trial termination

YQ23

almost3years

A Safety Study of YQ23 in Advanced Solid Tumors Patients (clinicaltrials.gov)

P1, N=30, Active, not recruiting, New Beta Innovation Limited | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Jun 2024

almost 3 years ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

Keytruda (pembrolizumab) • YQ23

4years

The anti-tumoral effects of the oxygen carrier YQ23 in a triple-negative breast cancer syngeneic model. (PubMed, Transl Cancer Res)

In concordance with the weakened immunosuppression, the inflammatory cytokine interferon γ and cytolytic granzyme B were upregulated. YQ23 treatment may be a potential therapeutic strategy to modulate the TME in TNBC.

4 years ago

Journal

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • GZMB (Granzyme B)

YQ23